[HTML][HTML] Androgen receptor signaling pathways as a target for breast cancer treatment

E Pietri, V Conteduca, D Andreis… - Endocrine-related …, 2016 - erc.bioscientifica.com
The androgen receptor (AR) is a ligand-dependent transcription factor, and its effects on
breast range from physiological pubertal development and age-related modifications to …

[PDF][PDF] Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer

S Dellapasqua, F Bertolini, V Bagnardi… - Journal of Clinical …, 2008 - researchgate.net
Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in
Advanced Breast Cancer Page 1 Metronomic Cyclophosphamide and Capecitabine …

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors

A Farolfi, E Melegari, M Aquilina, E Scarpi, T Ibrahim… - Heart, 2013 - heart.bmj.com
Objective Although adjuvant trastuzumab improves survival in patients with HER2-positive
early breast cancer, there is growing concern about the long-term effect of trastuzumab …

[HTML][HTML] Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

L Orlando, A Cardillo, R Ghisini, A Rocca, A Balduzzi… - BMC cancer, 2006 - Springer
Background HER2/neu overexpression is linked to promotion of angiogenesis in breast
cancer. We therefore tested the activity of the combination of Trastuzumab with metronomic …

Uncovering the genomic heterogeneity of multifocal breast cancer

C Desmedt, D Fumagalli, E Pietri… - The Journal of …, 2015 - Wiley Online Library
Multifocal breast cancer (MFBC), defined as multiple synchronous unilateral lesions of
invasive breast cancer, is relatively frequent and has been associated with more aggressive …

[HTML][HTML] Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

G Bronte, A Rocca, S Ravaioli, M Puccetti… - BMC cancer, 2018 - Springer
Background Androgen receptor (AR) is widely expressed in breast cancer (BC) but its role in
estrogen receptor (ER)-positive tumors is still controversial. The AR/ER ratio has been …

[HTML][HTML] Androgen receptor expression in breast cancer: what differences between primary tumor and metastases?

G Bronte, S Bravaccini, S Ravaioli, M Puccetti… - Translational …, 2018 - Elsevier
Genomic studies have shown that the androgen receptor (AR) pathway plays an important
role in some breast cancer subtypes. However few data are present on the concordance …

[HTML][HTML] Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non …

L Orlando, B Del Curto, S Gandini, R Ghisini, E Pietri… - The Breast, 2008 - Elsevier
PURPOSE: Topoisomerase IIα (Topo II) is a potential marker of responsiveness to
anthracycline-based therapy. We analyzed the role of Topo II gene status in the prediction of …

[HTML][HTML] The implication of liquid biopsies to predict chemoresistance in pancreatic cancer

E Pietri, R Balsano, M Coriano, F Gelsomino… - Cancer Drug …, 2021 - ncbi.nlm.nih.gov
Pancreatic cancer is one of the most aggressive diseases among solid tumors. Most patients
are diagnosed with advanced or metastatic disease and are characterized by poor …

Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy

A Rocca, D Andreis, A Fedeli, R Maltoni… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Pertuzumab is a recombinant, humanized monoclonal antibody that binds to
the dimerization domain of human epidermal growth factor receptor 2 (HER2), inhibiting the …